Successful suppression of cataplectic attacks with tramadol.
D000368:Aged; D015306:Biogenic Monoamines / Q000378:metabolism; D002385:Cataplexy / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D009025:Morpholines / Q000627:therapeutic use; D009294:Narcotics / Q000494:pharmacology / Q000627:therapeutic use*; D000077593:Reboxetine; D011957:Receptors, Opioid / Q000187:drug effects; D012008:Recurrence; D012895:Sleep, REM / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D014147:Tramadol / Q000494:pharmacology / Q000627:therapeutic use*; D014191:Tranylcypromine / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D015306:Biogenic Monoamines; D008996:Monoamine Oxidase Inhibitors; D009025:Morpholines; D009294:Narcotics; D011957:Receptors, Opioid; D014147:Tramadol; D014191:Tranylcypromine; D000077593:Reboxetine